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Abstract Disruptive technologies, such as communicative
reprogramming (anakoinosis) with cellular therapies in
situ for treating refractory metastatic cancer allow patient care
to accelerate along a totally new trajectory and highlight what
may well become the next sea change in the care of patients
with many types of advanced neoplasia. Cellular therapy in
situ consisted of repurposed drugs, pioglitazone plus all-trans
retinoic acid or dexamethasone or interferon-alpha (dual tran-
scriptional modulation) combined with metronomic low-dose
chemotherapy or low-dose 5-azacytidine, plus/minus classic
targeted therapy. The novel therapeutic tools for specifically
designing communication processes within tumor diseases fo-
cus on redirecting (1) rationalizations of cancer hallmarks
(constitution of single cancer hallmarks), (2) modular events,
(3) the ‘metabolism’ of evolutionary processes (the sum of
therapeutically and intrinsically inducible evolutionary pro-
cesses) and (4) the holistic communicative context, which
determines validity and denotation of tumor promoting com-
munication lines. Published data on cellular therapies in situ (6
histologic tumor types, 144 patients, age 0.9–83 years) in
castration-resistant prostate cancer, pretreated renal clear cell
carcinoma, chemorefractory acute myelocytic leukemia, mul-
tiple myeloma > second-line, chemorefractory Hodgkin lym-
phoma or multivisceral Langerhans cell histiocytosis, outline
the possibility for treating refractorymetastatic cancer with the
hope that this type of reprogrammed communication will be
scalable with minimal toxicity. Accessibility to anakoinosis is
a tumor inherent feature, and cellular therapy in situ addresses
extrinsic and intrinsic drug resistance, by redirecting conver-
gent organized communication tools, while been supported by
quite different pattern of (molecular-)genetic aberrations.
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Introduction
Currently proposed cancer models are favoring the selection
of theme-dependent therapeutic targets, i.e., tumor-promoting
pathways, specific epitopes etc. [1]. Despite the multifold ben-
eficial effects of classic targeted therapies, the underlying can-
cer models are stretched to their limits if mixed or poor re-
sponse occurs at metastatic sites, although the respective tar-
gets have been diagnostically proven [2].
One limitation of reductionist cancer models is the theme-
dependent attribution of tumor systems objects, i.e., cell com-
partments, pathologic pathways, oncogenes etc. to distinct
tumor features, e.g., hallmarks of cancer, such as
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inflammation, angiogenesis, immune response etc. [3]. Fre-
quently, genetic heterogeneity, just at metastatic sites, limits
validity of reductionist cancer models: Situate validity and
denotation of tumor systems participators are systems-and
stage-dependently highly diversified [4, 5].
Additionally, changing compositions of the tumor microen-
vironment during tumor progression and metastatic spread sug-
gest stage-dependent diversification of processes supporting
hallmarks of cancer, so called rationalizations [6, 7]. The sit-
uate diversity and redundancy of such rationalizations leads to
the assumption that we cannot precisely predict in developing
systems, such as in tumors, the situate validity and denotation of
single systems objects, i.e., cells, pathways, and therapeutic
targets etc. without administering novel read-out technologies
describing their situate functionality [8].
Insufficient treatment response based on reductionist de-
rived tumor models, leads to revising underlying hypotheses.
The importance of alternative therapy models may be proven
by systematically designing treatment approaches for
chemorefractory metastatic tumor diseases. ‘Cellular thera-
pies in situ’ are representing such novel approaches.
Primary aim of cellular therapies in situ is the communica-
tive reprogramming of tumor systems (anakoinosis) for di-
versifying palliative care, moreover, for uncovering novel ways
for the induction of tumor cell death. Cellular therapies in situ
comprise repurposed drugs [9, 10] with poor monoactivity, but
concerted regulatory activity, such as transcriptional modulators
(dual transcriptional modulation) [11–13], metronomic low-
dose chemotherapy [14], and classic targeted therapies [9].
The theoretical, communication based background has
been derived from phase II trials on cellular therapies in situ,
summarized in the ‘principles of modular tumor therapy’
[15, 16]. Cellular therapies in situ have the capacity for
rededicating functions and identities of cellular compartments
or tumor-promoting pathways, thereby attenuating tumor
growth (anakoinosis) without directly knocking down
tumor-promoting pathways or single cell compartments.
The summary on studies using cellular therapies in situ
impressively shows, to our knowledge for the first time, that
anakoinosis reproducibly mediates diversified novel systems
behaviors in chemorefractory tumors, and that communicative
reprogramming is able to depict and categorize targetable
communication tools in refractory tumor systems.
Material and Methods
For presenting tumor-associated communication tools as
valid therapeutic targets in systemically pretreated, refracto-
ry metastatic cancers or hematologic malignancies, we sum-
marized published clinical trials or compassionate use ap-
proaches, which uniquely introduced cellular therapies in situ.
The single components of cellular therapies in situ are
showing concerted regulatory activity, why toxicity can be
saved [16]. Cellular therapies in situ, presented here, consisted
of two major components, dual transcriptional modulation
[11–13] combinedwith drugs, whichmay enhance the activity
profile of transcriptional modulators, i.e., metronomic low-
dose chemotherapy (angiostatic, immune modulatory) [14]
or low-dose 5-azacytidine (epigenetic reprogramming). A
third component was added in some trials, namely classic
targeted therapies (imatinib, COX-2 inhibitors, lenalidomide
and mTor-inhibitors), again in a drug repurposing manner to
intensify the angiostatic, anti-inflammatory, and immune
modulatory activity profile (Table 1) [9, 10].
Dual Transcriptional Modulation Ligands of nuclear recep-
tors (NR) cue signaling response, establish ligand- nuclear
receptor links to transcription- and signal transduction layers,
induce gene expression changes, modulate cell type- and
ligand-dependent cell fate transitions [17] and finally - so the
present hypothesis—propose differential tumor- and involved
organ response.
At the cell level, cell fate transitions comprise the regula-
tion of a plethora of gene programs including, among others,
regulation of cell proliferation, metabolism and specific func-
tionalities that are acquired by differentiated cells. While the
early steps of NR function and their impact on organ physiol-
ogy is well understood, little is known about the dynamic gene
networks that ultimately cause or modulate a particular path-
ophysiological phenomenon, e.g., a hallmark of cancer, sup-
ported by respective NR ligands/hormones in tumor tissues.
Therapeutic dual transcriptional modulation aims at
reprogramming communication tools in tumor tissues for at-
tenuating tumor growth [11–13, 17].
Communicative Reprogramming To fill the gap in our un-
derstanding of cellular therapies in situ, particularly, on the
activity profile of transcriptional modulators in complex tissue
organizations, we operationalized the proposed communica-
tive reprogramming of tumor tissues according to classifiable
clinical phenomena arising during cellular therapies in situ.
Although, the systematization of tumor-associated commu-
nication tools is already a result of clinical observations during
and after cellular therapies in situ, we introduce these tools up-
front to present the respective clinical observations clearly
arranged [15, 16].
The novel therapeutic tools for specifically designing com-
municative reprogramming (anakoinosis) focus on four topics
[15], on redirecting (1) rationalizations of cancer hallmarks
(the diverse physical constitutions of single cancer hallmarks)
[18], (2) modular events (changing validity and denotation of
systems objects) [19], (3) the ‘metabolism’ of evolutionary
processes (the sum of extrinsically, i.e., therapeutically, and
intrinsically inducible evolutionary processes within the
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tumor compartment) and (4) the holistic communicative con-
text of structures, functions, decision maxims, i.e., hubs, in the
tumor compartment, which finally determines validity and
denotation of tumor promoting communication lines.
Phase I/II Trials and Compassionate Use Therapies Alto-
gether, 144 patients (age ranging from 11 months to 83 years)
suffering from six histologically different tumor types were
treated in three published phase II trials, one phase I trial,
and three compassionate use therapies (two already published)
and are now available for studying response behavior to cel-
lular therapy in situ: Two published phase II trials on metasta-
tic renal clear cell carcinoma (RCCC), trial II (n=31, 33 pa-
tients for intent-to-treat analysis) including pioglitazone and
interferon-alpha; trial I (n=18) including pioglitazone, serves
as historic control [20]; two published trials on castration-
resistant prostate cancer CRPC I (n=38); CRPC II (n=61)
[21, 22], differing in the metronomically administered cyto-
toxic drug, capecitabine (CRPC I) versus treosulfan (CRPC
II), and in an additional targeted therapy, imatinib (CRPC II);
one published phase I part of an on-going phase II trial for
multiple myeloma (MM, phase I, n=6, > = third line therapy,
retreatment with lenalidomide after IMiD failure was allowed)
[23], and two already published retrospective evaluations
(compassionate use) of patients with acute myelocytic
leukemia (AML, n=5) refractory to standard induction
chemorefractory [24], or chemo- and brentuximab-
vedotin-refractory classic Hodgkin lymphomas (cHL,
n=3, forth-line therapy) [25], and one, yet unpublished,
pediatric compassionate use therapy for chemorefractory
multivisceral Langerhans cell histiocytosis (third line
therapy in mLCH, n=2) in analogy to recently pub-
lished data on mLCH [26, 27].
The two consecutive eighteen and 11months old children
(girl/boy) with chemorefractory mLCH were treated after
informed consent by their parents on compassionate-use basis
as indicated in Tables 1 and 2. Treatment was performed in the
absence of alternative therapeutic options outside a clinical trial
and without formal institutional review board approval.
Some important activity profiles of anakoinosis induc-
ing regimens could be only shown after withdrawal of
patients from study due to developing resistance (CRPC II
trial, n=10); or non-oncologic surgical interventions (knee or
hip replacement in CRPC II trial, n=6) in case of preceding
prostate specific antigen response (PSA in serum <4 ng/mL).
The surgical patients, all having rapidly progressive disease at
study inclusion (PSA doubling time<3 months), were follow-
ed wi thou t any tumor spec i f i c the rapy, excep t
bisphosphonates, until PSA doubling. Ten patients with
CRPC were additionally treated with a gonadotropin-
Table 1 Anakoinosis: designing evolutionary processes in tumor tissues and exploiting and operationalizing their scope with cellular therapies in situ
Cellular therapy in situ
Anakoinosis: Designing evolutionary processes in tumor tissues and exploiting and operationalizing
their scope
Drug repurposing for communication
design
Anakoinosis promoting therapeutic tools: ‘Top down’ strategies
Dual transcriptional
modulation
Metronomic low-
dose
chemotherapy
Classic targeted therapy
Communication derived tools for
evolving tumor systems
Evolving tumor systems
• Targets are ubiquitously
distributed among tumor,
stroma and organ cells;
• Stimulating, not blocking
Modulation of
• Angiogenesis,
immune
response,
inflamation;
• Cell type
dependent
biomodulatory
activity
Drug repurposing
• Novel activity profile of targeted therapies
in the biomodulatory context;
• Pleiotropic novel activities
• Targeting rationalizations of cancer
hallmarks
• Targeting modular events
• Targeting the ‘metabolism’ of
evolutionary processes
• Targetring the holistic communicative
context by implementation of non-
normative boundary conditions
• Pioglitazoine (Actos)
45 mg p.o. daily
• All-trans retenoic acid
45 mg2 p.o. daily
• Interferon alpha 3MU s.c.
three times a week
Pioglitazone (Actos) 60 mg
p.o. daily
• Pioglitazone (Actos)
60 mg p.o. daily
Dexamethasone 0.5 to
1.0 mg daily
•Treosulfan 250 mg
twice daily
• Trofosfamide
50 mg thrice
daily
• Capecitabine 1 g
twice daily
• 5-azacytidine
75 mg absolute
7 days, every
4 weeks
• Low-dose lenalidomide (after lenalidomide failure)
15 mg p.o. daily
• Imatinib 400 mg p.o. daily
• mTor inhibitor (in Hodgkin lymphoma, everolimus,
serum level 15 ng/ml; in multivisceral Langerhans
cell histiocytosis, temsirolimus weight-adapted
in child)
• COX-2 inhibitor etoricoxib 60 mg p.o. daily or
rofecoxib 25 mg daily
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releasing hormone (GnRH) agonist, leuprorelinacetate, after
developing resistance to cellular therapy in situ, despite the
preceding resistance to GnRH agonists.
Redirecting Rationalizations of Cancer Hallmarks
Rationalizations in the present context describe the multifold
physical constitutions of single hallmarks of cancer [18]. The
constitution of rationalizations comprises multiple and, if
pathophysiologically required, exchangeable tumor cell com-
partments (redundancy) [28].
The following rationalizations for hallmarks of cancer were
clinically monitored:
& Inflammation response in serum: In RCCC (RCCC trial
I, II), mLCH and MM inflammation control was defined
as a >30 % decrease of C-reactive protein from base-line
[20, 23]. In cHL a normalization of CRP levels was con-
sidered critical as clinically relevant inflammation re-
sponse [25].
& In CRPC we followed immune response in one patient
with tumor-associated (paraneoplastic) lupus erythemato-
sus (CRPC I) [29].
The specific constitution of rationalization processes,
such as inflammation can be shown by inflammation control
following specific dual transcriptional modulation (Tables 1
and 2):
– In the RCCC II trial pioglitazone was supplemented by
low-dose interferon-alpha three times a week (Tables 1
and 2). Inclusion criteria in RCCC trial I, II were identi-
cal; therefore, a historic comparison of PFS and OS is
possible [20].
– In a 2 years old boy with chemorefractory multivisceral
Langerhans cell histiocytosis and insufficient inflamma-
tion control (fever) with pioglitazone / dexamethasone
besides metronomic low-dose chemotherapy,
temsirolimus was added in an adoptive therapy design
in analogy to the therapy schedule for cHL.
– Heterogeneity of response to anakoinotic therapy: In the
CRPC II trial PSA response was presented in waterfall
plots to depict therapy sensitivity and resistance of single
tumors [22].
Rearranging Modular Structures
Communication technically, cells are artifacts with situate
varying cellular identities and communication tools.
Modularity - in a novel definition - describes the degree
and specificity to which systems’ objects, i.e., cells, pathways,
Table 2 Cellular therapies in situ (trials and compassionate use programs) in pretreated or refractory hematologic malignancies or metastatic tumors
Cellular therapy in situ
Neoplasia Therapy-line No Metronomic
chemotherapy
Transcriptional
modulator
COX-2
inhibitor
Small molecule Publication
Renal clear cell carcinoma,
Phase II (RCCCI)
Unlimited number of
previous systemic
therapies
18 Capecitabine Actos COX-2
inhibitor
– Biomarker Insights,
2006
Renal clear cell carcinoma,
Phase II, (RCCCII)
Unlimited number
of previous systemic
therapies
45 Capecitabine Actos,
IFNalpha
COX-2
inhibitor
– World J Urol, 2002
Prostate cancer Phase II,
(CRPC II)
ClinicalTrilas.gov,
NCT00427999
Castration-resistant,
< 3 months PSA
doubling-time in
77 %
61 Treosulfan Actos, Dexa COX-2
inhibitor
Imatinib Cancer
Microenvironm.
2014
Prostate cancer,
Phase II (CRPC I)
Castration-resistant 36 Capecitabine Actos, Dexa COX-2
inhibitor
– World J Urol. 2013
Lancet Oncology,
2006
Langerhans cell
histiocytosis,
multivisceral
(compassionate use)
Third-line,
chemorefractory
2 Trofosfamide Actos, Dexa COX-2
inhibitor
−/+
Temsirolimus
Br. J. Haematol,
2005
Classic Hodgkin lymphoma
(compassionate use)
Forth-line,
chemorefractory
3 Treosulfan Actos, Dexa COX-2
inhibitor
Everolimus Br. J. Haematol,
2015
Acute myelocytic leukemia
(compassionate use)
Refractory to standard
induction
chemotherapy
5 5-azacytidine Actos,
Vesanoid
– – Haematologica,
2014
Multiple myeloma Phase I
ClinicalTrials.gov,
NCT001010243
>=3rd-line,
pretreatment
with lenalidomide
6 Treosulfan Actos, Dexa – Lenalidomide Blood 2012;
120:5029
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molecules, therapeutic targets etc. may be communica-
tively rededicated by anakoinosis that means, how they
alter their validity and denotation in the systems context
[15, 16].
Objective response of multiple pretreated, chemo- or
castration-resistant tumor diseases to cellular therapy in situ
may be achieved by modular events, that means without
specifically targeting any tumor promoting pathway, but by
communicatively rededicating validity and denotation of
tumor-promoting systems objects.
& Progression-free survival (PFS) was the primary end-
point of all prospective trials and was also studied in the
compassionate use projects.
& For CRPC I, II and RCCC I, II also survival data are
available [20–22].
& Tumor, leukemia and lymphoma cell death:
– Histopathological evaluation of complete remission
(CR in bone, lung) could be performed in RCCC II [20].
– Molecular CR (CRm) in AML: Leukemia cell death
could bemonitored bymorphology and polymerase chain
reaction (PCR) studies for molecular-genetic markers of
AML blasts at diagnosis [24].
– Histologic evaluation was possible at all metastatic sites
in both children with mLCH.
– Histologic and serologic confirmation of CR (serum and
urine) in MM [23].
& Disease chronification at minimal residual disease (pros-
tate-specific antigen, PSA<4.0 ng/mL) was studied in
CRPC II.
& Delayed response (partial remission, PR after>4 months)
in RCCC II and rapid response (<= 4 cycles, correspond-
ingly 4 months) was monitored in chemorefractory cHL
and AML [20, 24, 25].
Therapeutically Mediated Diversification of Evolutionary
Tools in the Tumor
The specific ‘metabolism’ of evolutionary processes in a
tumor may be considered as the sum of intrinsically and ther-
apeutically, via anakoinosis inducible evolutionary processes
within the tumor compartment.
Intrinsically occurring tumor-associated evolutionary pro-
cesses are characterized by the acquisition of molecular-
genetic heterogeneity [30, 31]. Cellular therapy in situ claims
to externally induce evolutionary processes via communica-
tive reprogramming of cellular tumor compartments. There-
fore, novel tumor systems behaviors may be clinically expect-
ed following induction of anakoinosis:
& Induction of biological memory means that tumor re-
growth is significantly delayed in comparison to the cor-
responding rapid progression at study inclusion (PSA
doubling time<3 months), although study medication
was withdrawn due to non-tumor related surgery. In
CRPC II, PSA doubling time prior to study inclusion has
been routinely studied.
& Restoration of hormone-sensitivity in CRPC was mon-
itored following development of resistance to study med-
ication by the add-on of leuprorelinacetate, while continu-
ing study medication.
& Further, sites of tumor response in RCCC II, cHL, and
mLCH were monitored. These observations give hints,
whether therapy response can be established at all meta-
static sites, despite the suggested molecular-genetic tumor
heterogeneity at metastatic sites.
& At relapse or progression,metastatic sites were routinely
monitored in the RCCC II trial to study, whether
anakoinotic therapy approaches may attenuate metastatic
spread [20].
& Molecular-genetic heterogeneity and induction of
anakoinosis: In AML, response could be correlated with
respective molecular-genetic aberrations at diagnosis [24].
& Differentiation response: In AML we studied
granulocytes for molecular-genetic aberrations found in
AML blasts at diagnosis [24].
& Patients with CRPC and lymph node metastases (CRPC
II) were routinely screened for objective response with CT
scans [22].
Holistic Communicative Context in theMicroenvironment
Determining Specific Pathologies
Tumor diseases are specified by characteristic tumor his-
tologies which arise on the basis of likewise tumor-
specific communication tools, operating among tumor
cells, their corresponding stromal surroundings and the
respective organ site. Cellular therapies in situ, as top-
down strategies interfere with those specific communi-
cation tools of a tumor, which are suggested to be ho-
listically organized for constituting typical tumor-stroma-
organ interactions.
Holist ic communicative conditions require a
communication-derived assessment of systems participators
from the participator’s view: That means communication with
a neighboring cell compartment in a tumor may not only alter
validity and denotation of the addressee, but simultaneously of
the addressor from the point of view of the addressee [15].
Therefore, monitoring biologic aspects of tumor
response should uncover novel cytological or histological re-
arrangements or imaging technical behaviors (PET scan, bone
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scan) depicting reciprocal communicative interactions within
tumor-stroma-organ compartments [22, 25].
In case of AML and MM bone marrow cytology and
blood count provide insights in communicative interac-
tions of leukemia cells and normal hematopoiesis [23,
24].
In Hodgkin disease, metabolic activity in the lesions
(PET scan) could be correlated with CRP response in serum
[25].
In the children with mLCH restoration of severely altered
organ functions could be monitored, in RCCC and CRPC
the CT-morphological behavior of osteolytic and osteoplastic
metastases, respectively.
In CRPC II, technetium up-take in bone lesions was mon-
itored by technetium scans during PSA response [22].
Safety and Quality of Life
For all patients safety data are available and already published,
except in case of mLCH (n=2). Data are given in the present
paper.
In CRPC data on quality of life during the first 6 months on
cellular therapy in situ are available [22].
Results
Modulation of the Tool of Rationalizations Constituting
Hallmarks of Cancer
Inflammation ControlA limited pattern of hallmarks of can-
cer could be clinically monitored, such as inflammation,
via CRP response, in RCCC I/II (n=18; n=31) (Fig. 1),
in MM (n=6) and mLCH (n=2), immune response in
one patient with CRPC (CRPC I) (Fig. 2).
Specification of anti-inflammatory therapy in RCCC II by
the add-on of low-dose interferon-alpha (Table 2) led to a
significant decline of CRP levels in serum, to a significantly
improved PFS and a tendency to improved OS in comparison
to the respective historical control group, receiving pioglita-
zone alone (RCCC I) (Fig. 1) [22, 32–34].
In MM response (long-term stable disease, partial
remission, very good partial remission and CR) was associat-
ed with >30 % CRP decrease (n=6) [23].
In cHL the CRP levels rapidly normalized (n=2) and PET
negativity ensues at quite different metastatic sites, in lymph
nodes, bone and lung lesions. One patient has shown no ele-
vated serum CRP levels at study inclusion, but also achieved
continuous complete remission cCR [25]. Long-term cCR
Metastac renal clear cell carcinoma
Speciﬁc raonalizaons of tumor-associated inﬂammaon
0 6 12 18 24 30 36
Study medicaon
Suninib
Sorafenib
Bevacizumab
Everolimus
Temsirolimus
Study medicaon
Months
OS
PFS
Phase II trial, second-line
(n=45)
Total study
population
Renal clear cell carcinoma, 
second-line therapy (two consecutive
trials)
Pioglitazone (Actos) 60 mg p.o. 
+/- Interferon alpha 3MU three times a week
Capecitabine (Xeloda) 1 g twice daily
Rofecoxib (Vioxx) 25 mg p.o.  
Cut-off: 
CRP decline >30%
CRP responder
p=0.03
Significantly prolonged survival in C-reactive protein
(CRP decline >30%) responders
Metastac renal clear cell carcinoma: Paents with
histologically conﬁrmed connuous complete
remission (n=3 >6 years ) 
Pioglitazone
without interferon-alpha 
Pioglitazone
plus interferon-alpha 
IL-6 has varied roles
and its effects are
highly context- and
tissue-dependent
IL-6 is largely
beneficial for tissue
homeostasis, with
roles in resolving
inflammation
IL-6 has
detrimental effects
during
carcinogenesis and
in chronic
inflammation
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Fig. 1 The addition of interferon-alpha to pioglitazone in pretreated renal clear cell carcinoma is associated with inflammation control, improved PFS
and OS in comparison with a historical control. PFS and OS data compare with those achieved in first-line with standard therapies
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was observed in two of three patients with cHL following
allogeneic blood stem cell transplantation.
In mLCH, CRP levels normalized in response to compas-
sionate use therapy (Fig. 3) [25].
Immune ResponseResolution of a tumor-accompanying sys-
temic lupus erythematosus occurred in CRPC I (n=1) within
14 days on treatment with study drugs. Immune response was
paralleled with objective tumor response (Fig. 2) [29].
Communication Tools, Available for Induction of
Anakoinosis may be Heterogeneous within a Histological-
ly Defined Tumor Type Waterfall plots for PSA response in
the CRPC trial II (Fig. 2) indicate differential sensitivity of
cellular therapy in situ: A percentage of 39 % CRPC patients
did not respond to cellular therapy in situ (PSA decline in
serum <50%), nevertheless OS for the total patient population
is nearly doubled compared to standard docetaxel therapy
[22].
mLCH In a 18 months old girl with chemorefractory
multivisceral LCH, weight-adapted metronomic low-dose
chemotherapy plus pioglitazone and dexamethasone induced
cCR (1 year+) in third-line (Fig. 3).
Only the adoptive change to pioglitazone/ dexamethasone
plus temsirolimus, besides metronomic low-dose chemother-
apy in third-line successfully resolved tumor-associated fever
in a 11 months old boy with chemorefractory mLCH,
resulting in histologically proven cCR (2 years +). The suc-
cessful therapeutic adoption indicates that inflammation/
angiogenesis and immune response may be differentially ra-
tionalized within mLCH diseases [26].
Therapeutically Exploiting Modular Events
The communicatively induced rededication of validity and
denotation of tumor-associated systems participators led to
objective responses in refractory (AML, cHL, mLCH, MM)
or repetitively progressive malignant diseases, i.e., in patients
with CRPC (77 % PSA doubling time<3 months) [22], and
patients with RCCC (RCCC II) [20].
Long-term chronification of CRPC with follow-up of
>4 to 6 years on therapy is possible (n=6), also in MM
(>3 years VGPR, n=1).
Castraon-resistant prostate cancer (CRPC II)
Combined transcriponal modulaon with pioglitazone plus dexamethasone
Castration-resistant prostate
cancer** (phase II)
(77% PSA doubling time < 3 
months)
Pioglitazone 60 mg p.o. daily
Dexamethasone 0.5 to 1.0 mg 
daily
Treosulfan (Ovastat) 250 mg 
twice daily
Etoricoxib 60 mg p.o.  
Imatinib 400 mg once daily
*Reichle A, ed. Evoluon-adjusted tumor pathophysiology, Springer 2013
Overall survival, n=61
PSA response**
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Fig. 2 A In the CRPC II trial, median OS has not been achieved after
3 years, although 39 % of the patients did not show objective response
(>50 % PSA response) to cellular therapy in situ. B Response in bone
scanwas observed in six of six patients.CControl of paraneoplastic lupus
erythematosus was associated with objective tumor response. D Therapy
response was on-going in six patients beyond stop of study medication (5
to 18 months) due to non-oncologic surgery. Following resistance to
cellular therapy in situ, 60 % of the studied patients regained
responsiveness against gonadotropin-releasing hormone (GnRH)
agonists
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Velocity of Response Objective responses occurred partly
very fast (<= 8 weeks) in very rapidly progressive
chemoresistant diseases, such as in CRPC (n=10, PSA
decline >50 %), AML (n=5), cHL (n=3), mLCH (n=2),
or in contrast, very delayed in RCCC II, after 4 to
6 months (10 of 15 responders, thereof n=2 pathologic
CRs).
Tumor, leukemia and lymphoma cell death (Table 3): In
all refractory or multifold pretreated malignancies, cell death
of malignant cells could be directly or indirectly monitored: In
the trial RCCC II, cCR>5 years (n=4), long-term OS
(>3 years, n=7) and pathologically confirmed CR in bone
(n=2) [20], inmLCH histologically confirmed CR at all met-
astatic sites (n=2, Fig. 3), CR in third-line of MM (1 of 6)
[23], molecular CR (3 of 5 patients) and cCR (n=1) in AML
[24], and in Hodgkin lymphoma PET negative PR (n=3)
[25]. In two of 13 patients with lymph node involvement,
treated in CRPC II trial, calcifications in involved lymph
nodes were found in CT scans as indicators for tumor necrosis
[22].
In CRPC II, OS did not achieve the median at 36 months
despite the negative selection of patients with 77 % PSA
doubling time<3 months before study inclusion. The median
OS for standard therapy with docetaxel is 19 months [35].
Survival in Pretreated Patients with RCCC (RCCC II)
Compares with Historic Controls Treated in First-Line
with Standard TherapiesMedian overall survival at 3 years
was 5 % in RCCC trial I versus 48 % in RCCC II, which
compares with first-line OS rates to standard therapies
(Fig. 1) [20].
Targeting the Specific Metabolism of Evolutionary
Processes
Cellular therapy in situ enables induction of qualitatively nov-
el tumor systems’ behaviors, as exemplarily shown by induc-
tion of differentiation in non-acute promyelocytic leukemia
(non-APL) patients (n=2) [24]; of biological memory
(CRPC II, n= 6), and reconstitution of hormone
responsiveness in CRPC (six of ten patients), and reduction
of the metastatic potential in RCCC II (21 of 31 patients,
68 % progression at the original metastatic sites) [16].
Adopve therapy design in mulvisceral chemorefractory 
Langerhans cell hisocytosis (mLC) or Hodgkin disease: 
Selecon of therapies for paents
Chemorefractory Hodgkin disease, forth-line Chemorefractory multivisceral Langerhans cell
histiocytosis (mLCH), children,11 and 18 months old
Pioglitazone (Actos) 45 mg p.o. daily (PPAR 
alpha/gamma agonist)
Pioglitazone (Actos) 15 mg p.o. daily (PPAR 
alpha/gamma agonist)
Dexamethasone (Fortecortin) 0.5 mg daily Dexamethasone (Fortecortin) 0.25 mg daily
Treosulfan (Ovastat) 250 mg once daily Trofosfamide (Ixoten) 50 mg once daily
Etoricoxib (Arcoxia) 60 mg p.o. daily (COX-2 inhibitor, 
PPAR beta antagonist)
Etoricoxib (Arcoxia) 15 mg p.o. daily (COX-2 inhibitor, 
PPAR beta antagonist)
Temsirolimus 25 mg once weekly Temsirolimus 5 mg once weekly
Hallmarks: Inﬂammaon, 
immune response, angiogenesis
Diﬀerenally
raonalized
hallmarks of
mLCH
Piglitazone (Actos)
15 mg p.o. daily
Dexamethasone
0.25 mg daily
Temsirolimus
5 mg once weekly
Both childs (11 and 18 months old) with chemorefractory LCH achieved
connuous complete remission >1 and >2 years
Pioglitazone (Actos) 
15 mg p.o. daily
Dexamethasone
0.25 mg daily
Reichle A. Langerhans‘ cellhisocytosis. Br.J.Haem
atol, 2005
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Fig. 3 Left site showing C-reactive protein (CRP) follow-up during
chemo- and brentuximab-vedotin refractory cHL. The add-on of
everolimus to combined transcriptional modulation with pioglitazone
and dexamethasone plus metronomic low-dose chemotherapy led to
PET negativity and continuous CR following allogeneic blood stem cell
transplantation. The right site indicates that chemorefractory mLCH may
respond with cCR following cHL-therapy without everolimus. But
patient two with chemorefractory mLCH needed the add-on of
temsirolimus to achieve cCR
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& Biological memory: Long-term chronification of CRPC
(CRPC II) after withdrawal of study medication (n=6)
reveals that dual transcriptional modulation may operate
evolutionary processes by simultaneously establishing ro-
bustness and homeostasis at the novel evolutionary level
(biological memory) (Fig. 2). It took 5 to 18 months until
PSA doubling. Transcriptionally induced reprogramming
of tumor compartments on an epigenetic level seems to
play a major role for inducing biological memory.
& Restoration of hormone sensitivity: Six out of ten pa-
tients with progressive disease on study medication have
shown a more than 50 % PSA response after addition of a
gonadotropin-releasing hormone (GnRH) agonist and
continuation of study medication.
& Differentiation: A novel phenomenon in AML was a
long-lasting ‘defect healing’ (>6 and 9 months disease
stability), characterized by maturation of non-APL blasts
in granulocytes with corresponding molecular-genetic ab-
errations of the blasts (n=2) [24].
Genetic Heterogeneity and Anakoinosis Observations in
RCCC II, AML, and cHL, together with the successful adop-
tive therapy design in mLCH, give hints that
& Cellular therapy in situ may successfully address
molecular-genetic heterogeneity at metastatic sites, which
is commonly associated with mixed tumor response to
classic targeted therapies, by concertedly designing still
preserved and uniquely constituted communication tools
at metastatic sites: Mixed responses in metastatic RCCC II
occurred rarely (23 %). No mixed responses were ob-
served in cHL and mLCH despite the suggested genetic
heterogeneity at metastatic sites.
& Despite molecular-genetic and genetic heterogeneity in
AML, these patients responded—even though qualitative-
ly different - to a unique therapeutic approach, at best with
molecular remission. This observation indicates the pres-
ence of convergent evolutionary processes accessible to
anakoinosis (Fig. 4) [24].
Targeting the Holistic Communicative Context in the Mi-
croenvironment Due to the holistic communicative context
in the microenvironment, ‚seed and soil’ are reciprocally ex-
changeable as indicated by the implementation of novel com-
municative reprogramming inducing boundary conditions,
i.e., cellular therapy in situ (Fig. 5, Tables 4 and 5). Induction
of response via non-theme-dependent targets reveals that the
communicative context of reductionist derived structures,
functions, and decision maxims, i.e., regulatory acting hubs,
are equally important in determining validity and denotation
of tumor promoting communication lines as reductionist at-
tributed functions of tumor systems objects.
As a consequence, cellular therapies in situ induce specific
functional changes likewise in tumor, adjacent stroma and
organ cells:
& Rapid restoration of the involved organ site, e.g., bone
marrow, could be achieved in AMLwith induction failure,
in 3 of 5 patients. With the administration of low-dose 5-
azacytidine, neutrophil counts in the peripheral blood in-
creased at each start of a 4 weeks cycle [24]. In contrast,
the approved cytotoxic doses of azacytidine are associated
with a decline of neutrophils in the peripheral blood [36].
& Unchanged, osteolytic ‘defect healing’ could be observed
in RCCC and MM. In CRPC osteoplastic metastases
remained stable, also in case of PSA response.
& In mLCH skin lesions (n=2) and severe mLCH associated
bone marrow insufficiency (n=2) resolved, however, fol-
lowing liver failure due to infiltration, the liver function
improved with severe defects (n=1), but lesions in the
intestine completely resolved (n=1). The boy was
Table 3 Indicating best responses to cellular therapies in situ
Anakoinosis inducing therapy elements: Dual transcriptional modulation and best response
Transcriptional
modulators
Metastatic diseases Remission induction? Best response Add-on of transcriptional modulators/
repurposed targeted therapies
Pioglitazone plus
dexamethasone
• Castration-resistant prostate cancer
• Multiple myeloma (third-line)
• Multivisceral Langerhans cell
histiocytosis (chemo-resistant)
• Hodgkin lymphoma (forth-line)
Minimal residual disease 6 years+
First CR in third-line, VGPR
33 months+
Continuous complete remission
(histologically Confirmed CR)
PET negativity
• Response after lenalidomide failure
• Everolimus
• Temsirolimus
Pioglitazone plus
interferon-alpha
• Renal clear cell carcinoma (second-
line)
Continuous complete remission
(Histologically confirmed CR)
• Interferon-alpha
Pioglitazone plus all-
trans retinoic acid
• Acute myelocytic leukemia
(refractory)
Continuous complete remission
(molecular CR)
• After 5-azacytidine failure rapid
response
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originally designated for combined liver and bone marrow
transplantation.
& Negative PETscan revealed significant metabolic changes
in cHL (n=3) during therapy despite the presence of re-
sidual disease in CT scans [25].
& Missing technetium up-take despite the unaltered presence
of osteoplastic metastases in CT scan was detected in 6 of
6 PSA responders (CRPC II) [22].
& InMM, hemoglobin levels increased in 4 of 6 pts>1.0 g/dl
during the 4 weeks core phase. That means hemoglobin
increase could not be due to rapid myeloma clearance in
the bone marrow [23].
Dual Transcriptional Regulation Stimulates Globally, Acts
Locally: Toxicity Profiles of Schedules Including Dual
Transcriptional Modulation are Modest
In CRPC toxicities grade 3 to 4 compare to abiraterone, but
no cardiotoxicity occurred. Quality of life measurements dur-
ing the first 6 months on therapy showed a stabilization of all
functions and no impairment compared to pulsed chemother-
apy (docetaxel) [22].
In RCCC trial I, II reported maximal toxicity was WHO
grade 3, predominantly due to hand-foot-syndrome
(capecitabine) [20].
AML: Compared with conventional myelosuppressive
chemotherapy regimens, treatment with 5-azacytidine,
pioglitazone and all-trans retinoic acid was associated
with much lower toxicity and could be easily adminis-
tered in an outpatient setting. The most common adverse
events were hematologic toxicities grade 1–4 without the
need for platelets or erythrocyte transfusions or adminis-
tration of growth factors [24].
CHL: Compared with conventional myelosuppressive
chemotherapy regimens, or brentuximab-vedotin therapy,
the treatment was associated with much lower toxicity
and could be easily administered in an out-patient setting
without any hospitalization during therapy. Even no
grade 3 or 4 hematologic toxicity occurred and there
was no need for platelets or erythrocyte transfusions or
administration of growth factors despite the heavily pre-
treatment of the three patients. Also no grade 3 or 4 non-
hematologic toxicities were observed. Dose reductions
were not necessary [25].
Working hypothesis: 
Convergent evoluonary processes
Raonalizaons: The non-genec counterpart of the genome
Broad heterogeneity of genetic signatures
constituting unique normative notions via specific rationalizations
Diverse, but restricted patterns of communication tools, 
which may be shared by histologically/cytogenetically different tumor types
Implementation of 
non-normative boundary conditions
in pathologic systems
Convergent evolutionary
processes
• Normativity, subjectivity
• Intersubjectivity 
• Modularity
Homeostasis, 
robustness
Evolution
Tumor-associated normative notions
(decision maxims, ‚hallmarks‘ of cancer, etc.)
Evolutionary confined, digitalized
• Structures, action norms
• Decision maxims
Metabolism of
Evolution
Modularized
therapy
Nodes
Hubs
Metastac
tumors:
Simultaneous
response at 
mulple organ
sites
Acute myelocyc 
leukemia:
Diverse cytogenec
aberraons respond to
an unique therapeuc
approach
Rapidly
displacing
growth
Interferon alpha
3MU three mes a 
week
Pioglitazone (Actos) 
45 mg p.o. daily
Pioglitazone (Actos) 
45 mg p.o. daily
Dexamethasone
0.5 to 1.0 mg daily
Pioglitazone (Actos) 
45 mg p.o. daily
All-trans renoic acid
45 mg/m2 daily
Form
al-pragm
ac
com
m
unicaon
theory
(Reichle A. Cancer M
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ent2009)
Fig. 4 Simultaneous tumor response at multiple metastatic tumor sites
and response of cytogenetically heterogeneous AMLs to a unique
therapeutic approach indicates that restricted pattern of communication
tools, particularly rationalizations of hallmarks of cancer, are uniquely
accessible with cellular therapies in situ
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MLCH: In the 11 months old boy high fever rapidly
resolved after start of cellular therapy in situ including
temsirolimus. Maximal toxicity observed was grade 3
hematotoxicity. Due to grade 3 hematotoxicity daily
weight adapted trofosfamide doses were reduced in both
patients.
MM: Patients experienced no dose-limiting toxicity at
both dose levels of lenalidomide (10 or 15 mg daily).
All patients continued treatment in the extension phase.
Serious adverse reactions observed during follow-up
were infections (n=6, Grade 2 NCI-CTCAE toxicity),
depressed mood (n=1, Grade 2), osteonecrosis of the
jaw and tooth extraction (n=1), and thrombosis during
anticoagulation (n=1, Grade 2) [23].
Cellular Therapies In Situ
Dual Transcriptional Modulation Pioglitazone was used in
combination with dexamethasone or all-trans retinoic acid or
interferon-alpha.
& In AML the add-on of pioglitazone to all-trans retinoic acid
led to a novel behavior of leukemia cells (differentiation,
leukemia cell death) and normal hematopoiesis (release of
neutrophils in peripheral blood) [24]. In RCCC (RCCC II),
the add-on of interferon-alpha decisively improved out-
come, based on inflammation control [20].
& Induction of anakoinosis with identical pairs of tran-
scriptional modulators, pioglitazone and dexamethasone
(Tables 1 and 2), mediated multifaceted clinical responses
in CRPC (CRPC II), cHL, MM and mLCH (Tables 4 and
5). Responses turned out to be heterogeneous in CRPC
(CRPC II) (waterfall blot, Fig. 2) [22].
Metronomic low-dose chemotherapy:
& Changing the drug for metronomic low-dose chemothera-
py, from capecitabine to treosulfan, improved in a historic
comparison both, median PFS and OS from 4.0 to
14.1 months, respectively, in the CRPC I trial, to a PFS
of 15.3 months and median OS, which has not been
achieved after 3 years (CRPC II trial) [21, 22].
Drug repurposing:
& Imatinib did not add any additional clinical benefit, even
in case of scheduled dose escalation (double dose) [22].
Cellular therapy in situ: Diversifying palliave care via anakoinosis
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• Connuous complete remission
A possible design space
Fig. 5 Cellular therapies in situ get access to the tumor’s design space via anakoinosis
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& However, either in cHL or in mLCH the add-on of an
mTor inhibitor could induce PET negativity and PR
(cHL) or continuous, histologically confirmed CR in
mLCH [25].
& Continuing a low-dose IMiD therapy within a cellular
therapy in situ after failure of IMiDs, may rescue MM
patients (n=1) [23].
& The impact of COX-2 inhibitors could not be evaluated in
the present designs of cellular therapies in situ.
Adoptive therapy
& For adopting anakoinotic constellations, drugs with
anakoinotic activity profile were selected (drug
repurposing); in AML low-dose azacytidine (epigenetic
reprogramming) [24], in mLCH or cHL, mTOR inhibitors
(immune modulatory, angiostatic) [25], in MM,
lenalidomide (immune modulatory) [23], and in several
tumor types COX-2 inhibitors (anti-inflammatory)
(Table 2). Also the chosen cytotoxic drugs for metronomic
chemotherapy seem to impact outcome (CRPC I/II).
& Adoptive therapy in an individual patient was success-
fully used in mLCH and cHL (Fig. 3), in a patient cohort
in RCCC (RCCC II).
Discussion
Diversified Modes of Palliative Care or Induction of Cure
by Cellular Therapy In Situ
Distant metastasis is the leading cause of cancer mortality.
Context-dependently changing validity and denotation of
tumor-promoting pathways [19, 30, 31, 37, 38], and genetic
heterogeneity at metastatic sites are major reasons for failure
of theme-dependent (pathway-,epitope-directed) targeted ther-
apy [39–41].
Table 4 The left column presents the two of four communication tools
(the holistic communicative context in the tumor microenvironment
andthe tool of rationalizations constituting hallmarks of cancer) and their
corresponding constraints, which specify the respective communication
processes. Themiddle column shows the communication technical targets
operated by anakoinosis. The right column summarizes therapeutic tools
accessible by anakoinosis
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Communicative reprogramming, i.e., anakoinosis, induced
by cellular therapies in situ turned out to consistently over-
come classic intrinsic, extrinsic resistance, and particularly
resistance due to (molecular-) genetic tumor heterogeneity,
as indicated by multiple modes of long-term tumor control,
even in small series of consecutively treated patients suffering
from refractory, metastatic tumor diseases or hematologic neo-
plasia with quite different histologic origin. Cellular therapies
in situ successfully overcome resistance by concertedly
redirecting convergent, but differentially organized com-
munication tools (Fig. 4), while been supported by quite dif-
ferent pattern of chromosomal and molecular-genetic aberra-
tions [24, 40, 41].
Induction of anakoinosis in chemorefractory metastatic
neoplasia is characterized by diversified response patterns
along the trajectory of tumor-specific communication tools.
The conceptual introduction and operationalization of com-
munication tools, which allows redirecting validity and deno-
tation of tumor-promoting systems participators (cells,
pathways etc.), is the starting point for the therapeutic turn-
around from a classic theme-dependent to a communication
oriented therapy strategy (Tables 4 and 5) [19].
Anakoinosis in Tumor Tissues: Categories for Designing
Communication Tools
For the first time, to our knowledge, comprehensive categories
for designing anakoinosis could be separated (Tables 4 and 5)
on the basis of systematic clinical observations during cellular
therapies in situ and after withdrawal due to tumor progression
or non-oncologic surgical interventions. The summarized
principles for communication- based therapeutic designs close
the gap, between available results describing communication
design on a molecular level in simplistic systems in vitro, for
example with transcriptional modulators [11–13, 17], and the
clinical observations derived on the scale of complex tissue
levels in refractory tumors.
Table 5 The left column presents the two of four communication tools
(modular events and the specific metabolism of evolutionary processes)
and their corresponding constraints, which specify the respective
communicat ion processes. The middle column shows the
communication technical targets operated by anakoinosis. The right
column summarizes therapeutic tools accessible by anakoinosis
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Anakoinosis describes the therapeutic accessibility of re-
ciprocal communicative interactions among biologic systems
participators, i.e., structures (cell compartments, pathways
etc.), functions (angiogenesis, immune response etc.) and de-
cision maxims (cellular hubs) via ubiquitously available, and
as shown, specifically targetable communication tools
(Tables 4 and 5, Fig. 7). The presented multifold therapeuti-
cally designed anakoinotic systems stages allow reconsidering
what tumor systems have in common, namely targetable,
seemingly elusive communication tools. Similar to immune
modulating therapies [42], the anakoinotically induced sys-
tems stages would not spontaneously develop via natural evo-
lutionary events.
An important observation is that normal organ systems are
obviously not as susceptible to anakoinosis as tumor systems
(Fig. 5). This is indicated by modest side effects of cellular
therapies in situ, even during long-term administration (CRPC
II, MM). Vice versa, tumors are downright characterized by
anakoinotic accessibility. Anakoinotic response profiles can
be now clinically categorized for therapeutically designing
communication tools (Tables 4 and 5) [15].
Tumor-associated rationalizations constituting hallmarks
of cancer are part of targetable communication tools [18].
Particularly rationalizations for immune response are already
systematized: Identical tumor immune responses may be
found at primary and metastatic sites [43, 44], and the kind
of immune response is predictive for survival [45].
Class ic targeted therapies s ingle out speci f ic
rationalizations as important targets for tumor control [46,
47]. All these therapies leave out of consideration that
rationalizations of hallmarks of cancer may have large varia-
tions in their constitution, and are often redundantly orga-
nized, such as angiogenesis [7], inflammation [16, 28, 48],
and immune response [44–46, 49] etc.
Just specific anakoinosis inducing schedules meet these
variations among the tumor-specific tools of rationalizations
by adoptive therapy approaches: This tool represents the tar-
getable, communication based non-genetic counterpart of the
genome (Tables 4 and 5).
The architectures of communication tools (Tables 4 and 5)
or rationalizations for hallmarks of cancer have in common
that theymay be unrelated to histologic tumor types or clinical
stages [44, 45], and - therapeutically decisive—are often sim-
ilarly organized at primary tumor sites and metastatic lesions
(rare mixed responses in RCCC II [16, 44].
Common anakoinotic processes among tumors, unique
constitutions of hallmarks of cancer in primary tumors and
metastatic sites as well as shared anakoinotic processes within
different histologic tumor types [7, 44, 45] support the claim
for an evolution-adjusted tumor pathophysiology for
Establishing a novel communicave
environment by cellular therapy insitu: 
Inducon of anakoinosis
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Diﬀerenal ways to tumor cell death
Anakoinosis: Novel ways for palliave care
Top-down approach: Reprogramming cell
compartments in the tumor (‚in situ‘)
Boom-up approach: 
Knocking down single pathways, cell compartments
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epitope, signalling pathways etc.
X = cellular targets
Fig. 6 Bottom-up and top-down strategies both redirect and modulate rationalizations constituting hallmarks of cancer, but are using separate techniques,
either theme-dependent targets or communicative reprogramming, i.e., anakoinosis
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guiding anakoinotic and rationalization oriented tumor thera-
pies (Fig. 6) [50].
Designing Cellular Therapies In Situ
The therapeutic elements of cellular therapies in situ are es-
tablishing ‘on-site’ novel boundary conditions, thereby,
accomplishing a virtual communicative context for
reprogramming tumor systems—importantly, in a reproduc-
ible and clinically relevant way (Tables 4 and 5).
Dual transcriptionalmodulation emerged as pivotal ther-
apeutic instrument for reprogramming tumor systems and for
uncovering and therapeutically exploiting basic communica-
tion tools (Tables 1 and 2). Therapies designing communica-
tion tools equivalently target stromal and tumor cells, which
are now considered as holistic communicative system (Fig. 7).
Specific anakoinotic processes may be induced - as shown -
regardless of whether tumors are predominantly consisting of
stromal cells, like in cHL, or of tumor cells, like in case of
AML (Fig. 7).
Drug Repurposing The paradigmatic shift from low-dose
metronomic dosing and considering cancer as targetable com-
municative system will be given priority in our approach to
the selection of drugs for repurposing. The intention is not to
look for new anti-proliferative cytotoxic agents or classic
targeted therapies that can be used at maximum tolerated
doses, the ‘magic bullets’, but to look for drugs from the
available clinical tool that can be used to support the redirec-
tion of tumor-specific communication tools. There is a clear
rationale for introducing combinations of regulatory acting
agents, which concertedly work on multiple communication
tools as indicated in Tables 4 and 5. The concerted regulatory
activity may even evolve tumor systems for generating novel
systems behaviors (Fig. 5).
Many targeted therapies, also those used in the current
trials, may be repurposed, as their activity profile is strongly
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Cellular
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Fig. 7 Anakoinosis inducing regimen may rescue refractory
malignancies regardless of whether tumors are predominantly
consisting of non-tumor cells, like in cHL, or of tumor cells, like in
case of AML. Traditionally, reductionist tumor models are focusing
separately on tumor and/or stroma cells (‘seed and soil’). Holistic
models are aiming at the communicative system, equivalently
constituted by tumor and stroma cells. The heterogeneous activity
profiles of anakoinosis, even within a single tumor disease, now figures
out fundamental limits to the precision with which certain pairs of
biological properties in the cell compartments can be predicted
simultaneously, particularly in tumor tissues. Comprehending and
monitoring cell identities and functions during various systems stages
of tumors will be of major interest in future for establishing anakoinosis
and should stimulate intensified research in the field of cellular secretome
analytics in blood serum or plasma
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dependent on the tumor type and stroma composition, and - as
shown by cellular therapies in situ - on the co-regulatory ac-
tivity profile of the combination partners [9, 51]. In
anakoinotic therapy schedules, the sum of single known drug
activities may establish a completely novel quality of action in
the tumor.
Metronomic low-dose chemotherapy is much better un-
derstood from its diverse interactions with rationalizations of
hallmarks of cancer, such as immune response and angiogen-
esis [14] and may support the activity profile of transcriptional
modulators [16, 52, 53]. Also the activity profile of low-dose
metronomic chemotherapy is strongly dependent on the his-
tologic tumor type or the tumor-specific communication tool,
respectively [48].
5-azacytidine at low doses induces differentiation and ac-
tivation of silenced genes. The clinical effects in non-APL
AML patients treated with 5-azacytidine, all-trans retinoic ac-
id and pioglitazone do not emerge in patient treated with the
single drugs or as add-on to chemotherapy [54, 55]: Even 5-
azacytidine at standard dose may be rescued by the triple
combination, and patients refractory to standard induction
therapy responded with CRm [24].
Principles for Communication- Based Therapeutic
Designs in Tumor Tissues and Constraints
Anakoinotic ‘operations’ may be summarized as principles
for communication- based therapeutic designs in tumor
tissues and their corresponding tumor-specific constraints
(Tables 4 and 5).Up-to-now the kind of anakoinotic reactivity
can be only poorly predicted on the basis of molecular param-
eters. Therefore, we defined principles for communication-
based therapeutic designs by defining constraints for design.
The constraints are characterized by communication specify-
ing key parameters as indicated in Tables 4 and 5.
In contrast to the commonly used reductionist definitions
for modularity (the degree to which collective functions of
systems participators are insulated from other components
and pathways [56]), we use now an exclusive communica-
tion-technical definition for modularity (communicative re-
dedication of validity and denotation of systems participators
[15]).
On the background of the novel definition and the system-
atization of communication principles in tumors, therapeutic
c o mm u n i c a t i o n d e s i g n r e p r e s e n t s a n o v e l
pathophysiologically relevant tool, even for inducing tumor
cell death in resistant disease, besides multifold beneficial
palliative treatment effects (Tables 4 and 5).
Therapeutically specifiable anakoinotic constellations
in metastatic tumors may be integrated in novel systems-
biological models to develop strategies for modifying tumor-
associated communication tools with adoptive cellular ther-
apies in situ (Fig. 7).
Therapeutically important is the fact that anakoinotic com-
munication tools may be shared by histologically unrelated
tumors [7] and by metastatic sites within an individual tumor
disease [16, 44]: Anakoinotic response to dexamethasone plus
pioglitazone was established in cHL, LCH, CRPC, and MM,
and to pioglitazone plus all-trans retinoic acid in AML and
pre-clinically in breast cancer [11, 24]. However, the pheno-
typic expression of anakoinosis among different histologic
tumor types is qualitatively different as indicated by charac-
teristic clinical features: The communicative background in
the respective tumor specifically determines the phenotypic
facets of anakoinosis.
The molecular basis of processes inducing anakoinosis
needs to be evaluated further, particularly anakoinotic constel-
lations leading to tumor cell death.
Uncovering Tumor Systems Biology by Anakoinosis
In future, novel tumor models (Fig. 7) will define
communication-technically exploitable resources for promot-
ing anakoinosis with cellular therapies in situ: Top-down - in
contrast to bottom-up approaches (Fig. 6) - reconsider com-
municative prerequisites determining situate validity and de-
notation of single tumor-promoting pathways or targets, the
contingently organized communication tools (Fig. 4), and the
uncertainty principle concerning the situate function of cel-
lular tumor compartments (Fig. 7)—as shown for example in
the diversified anakoinotic responses in AML, mLCH or in
the CRPC II trial.
The heterogeneous activity profiles of anakoinosis induc-
ing regimen, even within a single histologically defined tumor
disease, now figure out fundamental limits to the precision
with which certain pairs of biological properties in cell com-
partments can be predicted simultaneously, particularly in tu-
mor tissues and different tumor sites. Tumor-associated com-
municative constellations provided for anakoinosis, should be
consecutively analyzed, analytically or empirically at the
bench and may be retranslated into new communicative sys-
tems interpretations. Thus, the methodology may partially re-
verse the traditional information flow, which is affected by the
predominant transfer from analytical sciences to applied sci-
ences [57].
Comprehending and monitoring cell identities and func-
tions during various systems stages of tumors will be of major
interest in future for establishing purposefully anakoinosis and
should stimulate intensified research in the field of cellular
secretome analytics in blood serum or plasma [8, 58].
Differential selection of specific anakoinotic processes for
reprogramming tumor cell compartments may offer complete-
ly novel possibilities for diversifying therapeutic instruments
aiming at long-term tumor control. These promising data with
anakoinosis inducing combination therapies in chemo-
refractory neoplasia warrant further investigation in clinical
90 C. Hart et al.
trials. Perspectival, also patients at risk for acquiring tumor
diseases could benefit from novel anakoinosis inducing
schedules.
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